Drugs /

e7046

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, E7046 selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.

Clinical Trials

View Clinical Trials for e7046

E7046 has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating e7046, 4 are phase 1 (3 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for e7046 clinical trials.

Breast carcinoma, cervical carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in e7046 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating E7046
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating E7046
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating e7046 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
an0025, prostaglandin e ep4 receptor antagonist e7046, e 7046, ep4 antagonist e7046, ep4 inhibitor e7046, e-7046, prostaglandin e2 ep4 receptor inhibitor e7046, an0025, palupiprant
NCIT ID [1]:
C129689

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.